A Multicenter Open-label Study Of Etanercept Withdrawal And Retreatment In Subjects With Non-radiographic Axial Spondyloarthritis Who Achieved Adequate 24 Week Response
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Etanercept (Primary)
- Indications Ankylosing spondylitis; Connective tissue disorders; Musculoskeletal disorders
- Focus Therapeutic Use
- Acronyms RE-EMBARK
- Sponsors Pfizer
- 10 Jun 2017 Biomarkers information updated
- 30 Mar 2017 Planned End Date changed from 26 Oct 2019 to 4 Nov 2019.
- 30 Mar 2017 Planned primary completion date changed from 26 Oct 2019 to 18 Jul 2019.